US6696561B1
(en)
|
1909-07-09 |
2004-02-24 |
Basf Aktiengesellschaft |
Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport
|
US2779780A
(en)
|
1955-03-01 |
1957-01-29 |
Du Pont |
1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
|
JPS6041077B2
(ja)
|
1976-09-06 |
1985-09-13 |
喜徳 喜谷 |
1,2‐ジアミノシクロヘキサン異性体のシス白金(2)錯体
|
US4261989A
(en)
|
1979-02-19 |
1981-04-14 |
Kaken Chemical Co. Ltd. |
Geldanamycin derivatives and antitumor drug
|
US4475196A
(en)
|
1981-03-06 |
1984-10-02 |
Zor Clair G |
Instrument for locating faults in aircraft passenger reading light and attendant call control system
|
US4447233A
(en)
|
1981-04-10 |
1984-05-08 |
Parker-Hannifin Corporation |
Medication infusion pump
|
US4439196A
(en)
|
1982-03-18 |
1984-03-27 |
Merck & Co., Inc. |
Osmotic drug delivery system
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
US4447224A
(en)
|
1982-09-20 |
1984-05-08 |
Infusaid Corporation |
Variable flow implantable infusion apparatus
|
US4487603A
(en)
|
1982-11-26 |
1984-12-11 |
Cordis Corporation |
Implantable microinfusion pump system
|
US5030453A
(en)
|
1983-03-24 |
1991-07-09 |
The Liposome Company, Inc. |
Stable plurilamellar vesicles
|
US4486194A
(en)
|
1983-06-08 |
1984-12-04 |
James Ferrara |
Therapeutic device for administering medicaments through the skin
|
US4596556A
(en)
|
1985-03-25 |
1986-06-24 |
Bioject, Inc. |
Hypodermic injection apparatus
|
US5374548A
(en)
|
1986-05-02 |
1994-12-20 |
Genentech, Inc. |
Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
|
MX9203291A
(es)
|
1985-06-26 |
1992-08-01 |
Liposome Co Inc |
Metodo para acoplamiento de liposomas.
|
US4790824A
(en)
|
1987-06-19 |
1988-12-13 |
Bioject, Inc. |
Non-invasive hypodermic injection device
|
US4941880A
(en)
|
1987-06-19 |
1990-07-17 |
Bioject, Inc. |
Pre-filled ampule and non-invasive hypodermic injection device assembly
|
US5108921A
(en)
|
1989-04-03 |
1992-04-28 |
Purdue Research Foundation |
Method for enhanced transmembrane transport of exogenous molecules
|
US5032401A
(en)
|
1989-06-15 |
1991-07-16 |
Alpha Beta Technology |
Glucan drug delivery system and adjuvant
|
US5266573A
(en)
|
1989-08-07 |
1993-11-30 |
Elf Sanofi |
Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders
|
US5312335A
(en)
|
1989-11-09 |
1994-05-17 |
Bioject Inc. |
Needleless hypodermic injection device
|
US5064413A
(en)
|
1989-11-09 |
1991-11-12 |
Bioject, Inc. |
Needleless hypodermic injection device
|
US5383851A
(en)
|
1992-07-24 |
1995-01-24 |
Bioject Inc. |
Needleless hypodermic injection device
|
EP0647450A1
(en)
|
1993-09-09 |
1995-04-12 |
BEHRINGWERKE Aktiengesellschaft |
Improved prodrugs for enzyme mediated activation
|
US6977244B2
(en)
|
1996-10-04 |
2005-12-20 |
Board Of Regents, The University Of Texas Systems |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
US5891467A
(en)
|
1997-01-31 |
1999-04-06 |
Depotech Corporation |
Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
CN101818145A
(zh)
|
1998-03-20 |
2010-09-01 |
联邦科学和工业研究组织 |
控制基因表达
|
HUP0104693A3
(en)
|
1998-12-16 |
2003-12-29 |
Warner Lambert Co |
Treatment of arthritis with mek inhibitors
|
WO2000044914A1
(en)
|
1999-01-28 |
2000-08-03 |
Medical College Of Georgia Research Institute, Inc. |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
JP2002542263A
(ja)
|
1999-04-21 |
2002-12-10 |
ワイス |
ポリヌクレオチド配列の機能を阻害するための方法および組成物
|
PE20010306A1
(es)
|
1999-07-02 |
2001-03-29 |
Agouron Pharma |
Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
|
EP1194556A1
(en)
|
1999-07-09 |
2002-04-10 |
American Home Products Corporation |
Methods and compositions for preventing the formation of aberrant rna during transcription of a plasmid sequence
|
DE10160151A1
(de)
|
2001-01-09 |
2003-06-26 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
|
DE10100586C1
(de)
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
RU2164944C1
(ru)
|
1999-12-09 |
2001-04-10 |
Институт молекулярной биологии им. В.А. Энгельгардта РАН |
Способ изменения генетических свойств организма
|
GB0018891D0
(en)
|
2000-08-01 |
2000-09-20 |
Novartis Ag |
Organic compounds
|
CA2403397A1
(en)
|
2000-03-16 |
2001-09-20 |
Genetica, Inc. |
Methods and compositions for rna interference
|
MXPA02009069A
(es)
|
2000-03-17 |
2004-04-05 |
Benitec Australia Ltd |
Silenciamiento genetico.
|
AU2001260140A1
(en)
|
2000-03-22 |
2001-10-03 |
Avntis Pharma Deutschland Gmbh |
Nematodes as model organisms for the investigation of neurodegenerative diseases, in particular parkinsons disease, uses and methods for the discovery of substances and genes which can be used in the treatment of the above disease states and identification of a nematode gene.
|
AU2001249622B2
(en)
|
2000-03-30 |
2007-06-07 |
Massachusetts Institute Of Technology |
RNA sequence-specific mediators of RNA interference
|
CA2410947A1
(en)
|
2000-05-30 |
2001-12-06 |
Johnson & Johnson Research Pty Limited |
Methods for mediating gene suppresion by using factors that enhance rnai
|
US6680068B2
(en)
|
2000-07-06 |
2004-01-20 |
The General Hospital Corporation |
Drug delivery formulations and targeting
|
AU2001273498B2
(en)
|
2000-07-19 |
2006-08-24 |
Warner-Lambert Company |
Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
|
US20030166064A1
(en)
|
2000-08-03 |
2003-09-04 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of colon cancer
|
KR100909681B1
(ko)
|
2000-12-01 |
2009-07-29 |
막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. |
Rna 간섭을 매개하는 작은 rna 분자
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US20040234586A1
(en)
|
2001-06-11 |
2004-11-25 |
Sylvain Meloche |
Compositions and methods for enhancing nucleic acid transfer into cells
|
ATE468861T1
(de)
|
2001-08-16 |
2010-06-15 |
Univ Pennsylvania |
Synthese und verwendung von reagenzien für die verbesserte dna-lipofektion und/oder prodrug- und arzneimitteltherapien mit langsamer freisetzung
|
DE10230997A1
(de)
|
2001-10-26 |
2003-07-17 |
Ribopharma Ag |
Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
|
EA008379B1
(ru)
|
2002-02-01 |
2007-04-27 |
Ариад Джин Терапьютикс, Инк. |
Фосфорсодержащие соединения и их применения
|
EP2455467B1
(en)
|
2002-02-01 |
2016-10-05 |
Life Technologies Corporation |
Double-stranded oligonucleotides
|
RU2312861C2
(ru)
|
2002-03-05 |
2007-12-20 |
Мерк Фросст Кэнада Лтд. |
Ингибиторы катепсин-цистеинпротеазы
|
EP2308861B1
(en)
|
2002-03-08 |
2017-03-01 |
Eisai R&D Management Co., Ltd. |
Macrocyclic compounds useful as pharmaceuticals
|
TWI343377B
(en)
|
2002-03-13 |
2011-06-11 |
Array Biopharma Inc |
N3 alkylated benzimidazole derivatives as mek inhibitors
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
DE60334618D1
(de)
|
2002-06-28 |
2010-12-02 |
Protiva Biotherapeutics Inc |
Verfahren und vorrichtung zur herstellung von liposomen
|
EP1658304A4
(en)
|
2002-09-28 |
2009-01-14 |
Massachusetts Inst Technology |
THERAPY ANTIGRIPPALE
|
EP1560931B1
(en)
|
2002-11-14 |
2011-07-27 |
Dharmacon, Inc. |
Functional and hyperfunctional sirna
|
US7217807B2
(en)
|
2002-11-26 |
2007-05-15 |
Rosetta Genomics Ltd |
Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
|
ES2343318T3
(es)
|
2002-11-26 |
2010-07-28 |
University Of Massachusetts |
Administracion de arnsis.
|
US20040208921A1
(en)
|
2003-01-14 |
2004-10-21 |
Ho Rodney J. Y. |
Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
|
WO2004080406A2
(en)
|
2003-03-07 |
2004-09-23 |
Alnylam Pharmaceuticals |
Therapeutic compositions
|
WO2004091515A2
(en)
|
2003-04-09 |
2004-10-28 |
Alnylam Pharmaceuticals, Inc. |
iRNA CONJUGATES
|
JP4912873B2
(ja)
*
|
2003-04-09 |
2012-04-11 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
iRNA複合体
|
EP1648519B1
(en)
|
2003-07-16 |
2014-10-08 |
Protiva Biotherapeutics Inc. |
Lipid encapsulated interfering rna
|
WO2005021749A1
(en)
|
2003-08-28 |
2005-03-10 |
Novartis Ag |
Interfering rna duplex having blunt-ends and 3’-modifications
|
US7399865B2
(en)
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
AU2005248147A1
(en)
|
2004-05-11 |
2005-12-08 |
Alphagen Co., Ltd. |
Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
|
US7740861B2
(en)
|
2004-06-16 |
2010-06-22 |
University Of Massachusetts |
Drug delivery product and methods
|
PT1789390E
(pt)
|
2004-09-02 |
2012-02-08 |
Genentech Inc |
Inibidores de piridilo da sinalização de hedgehog
|
US20090012018A1
(en)
|
2004-09-13 |
2009-01-08 |
Matthias Hebrok |
Inhibition of pancretic cancer cell growth
|
JP5031587B2
(ja)
|
2005-02-10 |
2012-09-19 |
アメリカ合衆国 |
β−カテニンスプライス変異体を用いた癌の診断および処置の方法
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
CA2618218C
(en)
|
2005-07-21 |
2015-06-30 |
Ardea Biosciences, Inc. |
N-(arylamino)-sulfonamide inhibitors of mek
|
US8101741B2
(en)
|
2005-11-02 |
2012-01-24 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
US20100105134A1
(en)
|
2007-03-02 |
2010-04-29 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting gene expression and uses thereof
|
WO2008109369A2
(en)
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
|
EA018986B1
(ru)
*
|
2007-05-01 |
2013-12-30 |
Сантарис Фарма А/С |
Соединения-антагонисты рнк для модуляции активности бета-катенина
|
JP5726520B2
(ja)
|
2007-05-22 |
2015-06-03 |
アークトゥラス・セラピューティクス・インコーポレイテッドArcturus Therapeutics,Inc. |
治療剤のためのunaオリゴマー
|
US20080311081A1
(en)
*
|
2007-06-15 |
2008-12-18 |
Johannes Fruehauf |
Bacteria mediated gene silencing
|
MX338504B
(es)
|
2007-09-12 |
2016-04-20 |
Genentech Inc |
Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
|
JP5348725B2
(ja)
|
2007-10-25 |
2013-11-20 |
ジェネンテック, インコーポレイテッド |
チエノピリミジン化合物の製造方法
|
KR20100089869A
(ko)
*
|
2007-11-05 |
2010-08-12 |
노파르티스 아게 |
Wnt 활성화의 측정 및 wnt-관련 암의 치료를 위한 방법 및 조성물
|
AU2008342535B2
(en)
|
2007-12-27 |
2015-02-05 |
Arbutus Biopharma Corporation |
Silencing of polo-like kinase expression using interfering RNA
|
US8168784B2
(en)
|
2008-06-20 |
2012-05-01 |
Abbott Laboratories |
Processes to make apoptosis promoters
|
TWI455944B
(zh)
*
|
2008-07-01 |
2014-10-11 |
Daiichi Sankyo Co Ltd |
雙股多核苷酸
|
EP2266550A1
(en)
|
2009-06-15 |
2010-12-29 |
Institut Curie |
Antagonists of ß-catenin for preventing and/or treating neurodegenerative disorders
|
CA2677068A1
(en)
|
2009-09-01 |
2011-03-01 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting gene expression and uses thereof
|
JP5781518B2
(ja)
|
2009-10-16 |
2015-09-24 |
ユニバーシティ・ヘルス・ネットワーク |
ポルフィリンナノ小胞
|
MX339050B
(es)
|
2009-12-18 |
2016-05-09 |
Novartis Ag |
Composiciones organicas para tratar las enfermedades relacionadas con hsf1.
|
DK2591105T3
(en)
|
2010-07-06 |
2017-07-31 |
Dicerna Pharmaceuticals Inc |
METHODS AND COMPOSITIONS FOR SPECIFIC INHIBITION OF BETA-CATENIN USING DOUBLE-STRENGTH RNA
|
CA2805265A1
(en)
*
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|